Media Coverage

VistaGen out-licenses rights to anxiety disorder candidate in Asia territories

VistaGen out-licenses rights to anxiety disorder candidate in Asia territories

Jun 26, 2020

DocTalk Podcast: The Psychological Damage of the COVID-19 Pandemic

DocTalk Podcast: The Psychological Damage of the COVID-19 Pandemic

May 27, 2020

An interview with Shawn Singh: Chief Executive Officer and Director of VistaGen Therapeutics

An interview with Shawn Singh: Chief Executive Officer and Director of VistaGen Therapeutics

Mar 12, 2020

VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial

VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial

Feb 21, 2020

FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

Feb 4, 2020

Investigational Dyskinesia Treatment Gets FDA Green Light

Investigational Dyskinesia Treatment Gets FDA Green Light

Feb 3, 2020

VistaGen to study dyskinesia drug in Phase II Parkinson’s trial

VistaGen to study dyskinesia drug in Phase II Parkinson’s trial

Jan 31, 2020

FDA Clears Study to Test New Drug to Treat Dyskinesia for Parkinson Patients

FDA Clears Study to Test New Drug to Treat Dyskinesia for Parkinson Patients

Jan 30, 2020

Intranasal Therapy Fast-Tracked for Social Anxiety Disorder

Intranasal Therapy Fast-Tracked for Social Anxiety Disorder

Dec 19, 2019

Long-Term Use of Benzodiazepines – Avoiding Another Drug Crisis

Long-Term Use of Benzodiazepines – Avoiding Another Drug Crisis

Nov 20, 2019